Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

148.50p
   
  • Change Today:
      1.50p
  • 52 Week High: 148.50
  • 52 Week Low: 107.50
  • Currency: UK Pounds
  • Shares Issued: 106.23m
  • Volume: 18,089
  • Market Cap: £157.75m
  • RiskGrade: 126

Results Round-up

Date: Thursday 19 Mar 2015

LONDON (ShareCast) - Results from marketing group Cello Group hit a bum note with investors despite pleasing profits growth, a healthy hike in the dividend and a solid start made to 2015.
Shares in the AIM-listed company fell despite chief executive Mark Scott hailing the improvement in fortunes as Cello became established as a "global player" in the pharmaceutical space, as it was the first full year of trading under the unified Cello Health brand.

Revenue rose 6.4% to £169.9m in 2014, with gross profit up 8.4% to £81m and headline profit before tax up 9.9% to £9.4m.

Headline basic earnings per share climbed 12.3% to 8.14p and despite operating cash flow more than halving to £4.8m - reflecting excessive cash conversion the year before - the dividend was lifted 15.6% to 2.6p.



A sharp increase in lending to customers saw Arbuthnot Banking Group's annual pre-tax profit jump 43% to £22.5m.

The group, which includes private banking business Arbuthnot Latham & Co Limited and retail banking arm Secure Trust Bank, said its lending to customers rose to a record high of £1.1bn, while net interest income rose 34.2% to £98m.

The growth in pre-tax profit was 4% higher than expected by Numis prompting the brokerage to describe the full year results as a "strong" performance sure to warrant an increase in forecast and target price.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 148.50p
Change Today 1.50p
% Change 1.02 %
52 Week High 148.50
52 Week Low 107.50
Volume 18,089
Shares Issued 106.23m
Market Cap £157.75m
RiskGrade 126

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
77.17% below the market average77.17% below the market average77.17% below the market average77.17% below the market average77.17% below the market average
5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average
Price Trend
68.80% above the market average68.80% above the market average68.80% above the market average68.80% above the market average68.80% above the market average
56.10% above the sector average56.10% above the sector average56.10% above the sector average56.10% above the sector average56.10% above the sector average
Income
28.7% below the market average28.7% below the market average28.7% below the market average28.7% below the market average28.7% below the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Growth
29.85% below the market average29.85% below the market average29.85% below the market average29.85% below the market average29.85% below the market average
54.29% below the sector average54.29% below the sector average54.29% below the sector average54.29% below the sector average54.29% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Interim Final
Ex-Div 03-Oct-19 25-Apr-19
Paid 01-Nov-19 24-May-19
Amount 1.15p 2.75p

Trades for 21-Feb-2020

Time Volume / Share Price
13:07 169 @ 147.50p
12:32 1,250 @ 147.50p
12:18 10,000 @ 147.25p
12:18 1,000 @ 148.00p
11:09 820 @ 148.00p

Cello Health Key Personnel

CEO Mark Scott

Top of Page